BACKGROUND: Serum levels of some soluble adhesion molecules (e.g. ICAM-1, or E-selectin) are higher in some patients with breast cancer (especially metastatic) compared to controls. They bring about the increased risk of developing metastases and they can negatively influence the prognosis of patients. The aim of our study was to assess the serum levels of several soluble adhesion molecules (soluble E-selectin, P-selectin, ICAM-1, VCAM-1 and CD44s) in patients with breast cancer in clinical stage 0-IV before the beginning of hormonal therapy and/or chemotherapy. We wanted to find out if these parameters differ between various stages of breast cancer and if their levels are influenced by the therapy. METHODS AND RESULTS: We examined 59 mostly postmenopausal patients with breast cancer in clinical stage 0-IV (mean age was 62 years). One patient was in stage 0, 10 patients were in stage I, 24 patients were in stage IIA, 11 patients were in stage IIB, 5 patients were in stage III and 8 patients were in stage IV. Serum levels of soluble E-selectin, P-selectin, ICAM-1, VCAM-1 and standard form of CD44 were assessed using ELISA in sera of patients with breast cancer before the institution of hormonal therapy and/or chemotherapy and 3 and 12 months after the beginning of therapy. Compared to controls, patients with (metastatic and also non-metastatic) breast cancer before the beginning of therapy had higher serum levels of soluble E-selectin, P-selectin, ICAM-1 and standard form of CD44. Serum levels of E-selectin, ICAM-1 and also VCAM-1 significantly decreased one year after the beginning of therapy. Serum levels of soluble adhesion molecules mutually correlated and they also correlated with serum levels of soluble TNF and IL-2 receptors and some acute phase proteins (CRP and orosomucoid). CONCLUSIONS: Serum levels of some soluble adhesion molecules (E-selectin, P-selectin, ICAM-1 and CD44s) were higher in some patients with breast cancer and decreased again after hormonal therapy and/or chemotherapy. Only larger studies with longer follow-up may imply if any of these parameters (e.g. soluble P-selectin), or their combination may become useful marker of activity and/or outcome.

• MeSH
• dospělí MeSH
• karcinom krev   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• molekuly buněčné adheze krev   MeSH
• nádory prsu krev   terapie   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• molekuly buněčné adheze MeSH

BACKGROUND: Serum levels of C-reactive protein (CRP) and orosomucoid are increased in more than one half of patients with metastatic breast cancer. The information concerning their levels in non-metastatic breast cancer is inconclusive. The aim of our study was to examine some acute phase proteins (CRP, orosomucoid, prealbumin, alpha 2-macroglobulin and transferrin) in patients with various clinical stages of breast cancer before hormonal and/or chemotherapy and 3 and 12 months after its institution and to assess the influence of their levels on the outcome of patients. METHODS AND RESULTS: Altogether 59 women with breast cancer in clinical stage 0-IV, median age 62 years (47 of them after menopause) were examined. One patient was in stage 0, ten patients in stage I, 24 patients in stage IIA, 11 patients in stage IIB, five patients in stage III and eight patients in stage IV. Acute phase proteins (CRP, orosomucoid, transferrin, prealbumin and alpha 2-macroglobulin) were examined in the sera samples using microturbidimetry. Serum levels of CRP and orosomucoid were higher in patients with breast cancer in all stages compared to controls. Serum levels of CRP (resp. of orosomucoid) higher than mean +2 SD had 30.5% (resp. 39%) of patients with breast cancer. One year after the beginning of therapy serum levels of CRP and orosomucoid significantly decreased, however, in case of orosomucoid they remain higher compared to controls. Serum levels of CRP and orosomucoid correlated before therapy in patients with breast cancer one to another and also with serum levels of soluble TNF (tumour necrosis factor) receptor type I and soluble ICAM-1. IN CONCLUSION: Patients with breast cancer before hormonal therapy and/or chemotherapy had compared to controls increased serum levels of CRP and orosomucoid, however, there was no difference between stages I-III. Observed correlation between serum levels of CRP and soluble TNF receptors suggests the important role of proinflammatory cytokines in stimulating their hepatic synthesis also in patients with breast cancer. Putative prognostic role of persistently increased levels of orosomucoid in patients with non-metastatic breast cancer warrants further investigation.

• MeSH
• dospělí MeSH
• karcinom krev   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory prsu krev   terapie   MeSH
• prognóza MeSH
• proteiny akutní fáze analýza   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• proteiny akutní fáze MeSH

BACKGROUND: Our study was designed to monitor the presence of the "coronary artery disease (CAD) risk factors" after kidney transplantation. METHODS: 26 kidneys transplant recipients with well-functioning (creatinine clearance > 0.8 mL/s) renal allografts receiving cyclosporine A (CsA) as the basic component of immunosuppressive therapy and 60 healthy age-matched controls were included into the study. As "CAD risk factors" were determined the levels of fibrinogen, acute phase proteins orosomucoid and C-reactive protein, t-PA Ag, PAI-1 Ag and soluble adhesion molecules E-selectin, P-selectin and ICAM-1 in the peripheral blood serum or plasma. RESULTS: Renal transplant recipients showed higher BMI (p < 0.001) and levels of fibrinogen (p < 0.001), t-PA Ag (p = 0.007) and PAI-1 Ag (p < 0.001), acute phase protein orosomucoid (p < 0.001) and higher level of soluble P-selectin (p = 0.038). The levels of sICAM-1 and sE-selectin did not differ statistically significantly from those in controls. CONCLUSION: Our study has demonstrated renal graft recipients with good kidney function already show significantly raised levels of "CAD risk factors" fibrinogen, acute phase reactant orosomucoid, t-PA Ag, PAI-1 Ag and sP-selectin.

• MeSH
• fibrinogen analýza   MeSH
• inhibitor aktivátoru plazminogenu 1 krev   MeSH
• koronární nemoc diagnóza   etiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• P-selektin krev   MeSH
• proteiny akutní fáze analýza   MeSH
• rizikové faktory MeSH
• tkáňový aktivátor plazminogenu krev   MeSH
• transplantace ledvin škodlivé účinky   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• fibrinogen MeSH
• inhibitor aktivátoru plazminogenu 1 MeSH
• P-selektin MeSH
• proteiny akutní fáze MeSH
• tkáňový aktivátor plazminogenu MeSH

BACKGROUND: The object of this study was to examine the occurrence of iron deficiency anemia in women after spontaneous delivery, changes in clinical and laboratory indicators of anemia in postpartum period and their possible control by administration of peroral antianemics. METHODS: Ninety pregnant women at 35th to 39th week of gestation were randomly divided into three groups and extensively examined in a laboratory. After delivery, the mothers were examined four times at monthly intervals until the end of the third postpartum month. At the same time, they were examined for their subjective feeling of health, with some focus on typical anemic symptoms. Women in the first group were treated with 80 mg of elemental iron a day for the first two months after childbirth. Women in the second group were treated with 80 mg of elemental iron+0.35 mg of folic acid a day for the same period of time. Women in the control group did not use any medication. McNamara test was used to evaluate the portion of anemic and sideropenic women and for comparison between individual groups. RESULTS: Findings of the study have shown a faster adjustment of laboratory and clinical indicators of postpartum anemia in women treated with iron. We did not observe the only, sovereign marker of iron deficiency (sideropenic) anemia in the early postpartum period. CONCLUSIONS: We recommend flat administration of iron to all women after spontaneous delivery. Postpartum substitution with iron should last at least three months because of long-lasting sideropenia. Adding folic acid to iron does not have any significant impact during the postpartum period.

• MeSH
• anemie z nedostatku železa diagnóza   prevence a kontrola   MeSH
• biologické markery krev   MeSH
• dietní železo aplikace a dávkování   MeSH
• dospělí MeSH
• ferritiny krev   MeSH
• hematokrit MeSH
• hemoglobiny metabolismus   MeSH
• kyselina listová aplikace a dávkování   MeSH
• lidé MeSH
• počet erytrocytů MeSH
• poruchy v puerperiu diagnóza   prevence a kontrola   MeSH
• potravní doplňky * MeSH
• receptory transferinu krev   MeSH
• retikulocyty MeSH
• těhotenství MeSH
• železo aplikace a dávkování   krev   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• biologické markery MeSH
• dietní železo MeSH
• ferritiny MeSH
• hemoglobiny MeSH
• kyselina listová MeSH
• receptory transferinu MeSH
• železo MeSH

INTRODUCTION: Cytokines were shown both to enhance tumour growth and formation of metastases and to inhibit proliferation of tumour cells. TNF alpha may mediate apoptosis and necrosis of cancer cells, while the exact role of IL-2 remains to be elucidated. Plasma levels of TNF alpha and TNF and IL-2 soluble receptors (sTNF-R, sIL-2R) should thus be in some relation to some biological characteristics of the breast cancer. MATERIAL AND METHODS: Plasma levels of TNF alpha, sTNF-R I and II and sIL-2R were measured in 31 women with different stages of breast cancer both before the institution of therapy and after 3 months of the treatment. RESULTS: Plasma levels of both types of sTNF-Rs were higher in patients with breast cancer than in controls (sTNF-R I--2166.6 +/- 568.9 vs. 1121.3 +/- 260.6 pg/ml, p < 0.001, sTNF-R II--3792.8 +/- 958.9 vs. 1996.2 +/- 404.3 pg/ml, p < 0.001) with no significant difference between clinical stages. Plasma levels of both sTNF-R (0.871, p < 0.001) and sIL-2R tightly correlated with each other. Plasma levels of TNF alpha decreased after treatment (from 3.92 +/- 1.86 to 3.40 +/- 1.15 pg/ml, p < 0.01), but plasma levels of sTNF-Rs and sIL-2R were not influenced by the therapy. CONCLUSION: Plasma levels of soluble TNF receptors may thus serve as a non-specific marker of the untreated breast cancer. Their relation to other biologic characteristics of this tumour is not clear. It remains also to be clarified if the long-term treatment leads to the normalization of sTNF-Rs plasma levels.

• MeSH
• CD antigeny krev   MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádorové biomarkery krev   MeSH
• nádory prsu krev   patologie   terapie   MeSH
• receptory interleukinu-2 krev   MeSH
• receptory TNF - typ I MeSH
• receptory TNF - typ II MeSH
• receptory TNF krev   MeSH
• rozpustnost MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• staging nádorů MeSH
• studie případů a kontrol MeSH
• TNF-alfa metabolismus   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• CD antigeny MeSH
• nádorové biomarkery MeSH
• receptory interleukinu-2 MeSH
• receptory TNF - typ I MeSH
• receptory TNF - typ II MeSH
• receptory TNF MeSH
• TNF-alfa MeSH

OBJECTIVE: GH deficiency (GHD) is usually associated with a higher incidence of cardiovascular disease (CVD). The aim of this study was to establish whether patients with GHD, like those with CVD, show an increase in fibrinogen (FBG), type-1 plasminogen activator inhibitor (PAI-1), acute phase response proteins (APR), and soluble adhesion molecules. The effect of recombinant human GH (rhGH) replacement, on these parameters was also investigated. PATIENTS AND DESIGN: Concentrations of PAI-1 antigen (Ag), adhesion molecules sE-selectin, sP-selectin, and intercellular adhesion molecule-1 (sICAM-1), FBG and levels of APR orosomucoid (ORM), and 'negative APR' transferrin (TRF) were established in 11 panhypopituitary (PHP) patients (eight men and three women, age median 39.0 years, body mass index (BMI) 27. 49 +/- 3.89 kg/m2) before and after 12-month replacement with rhGH. Control values were obtained by examination of 33 healthy age and sex matched subjects (24 men and nine women with BMI 24.16 +/- 1.99 kg/m2). RESULTS: PHP patients had higher concentrations of ORM (0.80 +/- 0.25, vs. 0.61 +/- 0.20 g/l; P = 0.05), FBG (3.22 +/- 0.48, vs. 2.57 +/- 0.47 g/l; P = 0.001), PAI-1 Ag (97.12 +/- 33.23, vs. 44.11 +/- 21.40 microgram/l; P = 0.001), sE-selectin (72.42 +/- 28.35, vs. 42. 80 +/- 12.60 microgram/l; P = 0.004), sP-selectin (221.26 +/- 75.12, vs. 104.79 +/- 26.01 microgram/l; P = 0.001) sICAM-1 (409.75 +/- 137.78, vs. 228.10 +/- 37.54 microgram/l; P = 0.001), and lower levels of TRF (2.14 +/- 0.40, vs. 2.76 +/- 0.39 g/l; P = 0.001) than controls. After 12-month rhGH replacement the patients showed an increase of TRF (2.64 +/- 0.84 g/l, P = 0.037) and decrease of soluble adhesion molecules (sE-selectin 57.98 +/- 27.04 microgram/l, P = 0.01, sP-selectin 121.74 +/- 50.42 microgram/l, P = 0.007; and sICAM-1 279.95 +/- 88.32 microgram/l, P = 0.005), which then, similarly to the ORM (0. 67 +/- 0.12 g/l) and FBG level (2.82 +/- 0.51 g/l), did not statistically differ from the values in the control group. CONCLUSION: rhGH replacement led to modulation of the 'inflammatory response' in panhypopituitary patients. This modulation occurred locally at vascular endothelium level where after rhGH replacement, sE-selectin, sP-selectin and sICAM-1 concentrations decreased, a similar effect as in the systemic inflammatory response, as was also apparent from the changes in acute phase response protein levels.

• MeSH
• dospělí MeSH
• E-selektin analýza   MeSH
• fibrinogen analýza   MeSH
• inhibitor aktivátoru plazminogenu 1 analýza   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mezibuněčná adhezivní molekula-1 analýza   MeSH
• molekuly buněčné adheze krev   MeSH
• neparametrická statistika MeSH
• orosomukoid analýza   MeSH
• P-selektin analýza   MeSH
• rekombinantní proteiny terapeutické užití   MeSH
• růstový hormon nedostatek   terapeutické užití   MeSH
• studie případů a kontrol MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• E-selektin MeSH
• fibrinogen MeSH
• inhibitor aktivátoru plazminogenu 1 MeSH
• mezibuněčná adhezivní molekula-1 MeSH
• molekuly buněčné adheze MeSH
• orosomukoid MeSH
• P-selektin MeSH
• rekombinantní proteiny MeSH
• růstový hormon MeSH

The prevalence of anaemia during pregnancy and post partum is according to the literature and many years clinical experience high. In the submitted work we investigated the incidence of sideropenic anaemia in women during the first three months after a spontaneous delivery, changes of clinical and laboratory indicators of anaemia during this period and the possible effect exerted by administration of iron and iron plus folic acid resp. Ninety pregnant women in the 35th to 39th week of pregnancy were at random divided into three equally sized groups and the following were assessed: haemogram, indicators of iron reserves, serum concentrations of folic acid, vitamin B12, erythropoetin and soluble transferrin receptor, liver tests, total protein + electrophoresis, acute stage proteins. In the first group (T) the women were given, starting on the 4th day after delivery 1 tablet of Tardyferon per day for two months. To the second group (F) for an equal period 1 tablet of Tardyferon Fol per day was administered. Women in the control group (K) had no medication. In the investigation women with medium and severe pregnancy anaemia were not included nor women taking during pregnancy or previously iron preparations or those treated in the past by blood transfusion. After spontaneous delivery (women who had Caesarean section or forceps delivery were eliminated from the study) the women were subjected to the same examinations as before delivery. These examinations were made on the fourth day after delivery and then after monthly intervals for a period of three months. At the same time the subjective condition of the mothers was evaluated after delivery, focused on the development of symptoms typical for anaemia and the possible effect of administered treatment. The investigation was completed by 60 women. During treatment no allergic or other serious side-reactions to the administered drugs calling for discontinuation of treatment were recorded. The results of the investigation proved that laboratory and clinical indicators of post-partum anaemia reached more quickly normal values in women treated with iron preparations. The authors did not detect a single and supreme marker of sideropenic anaemia in the early post-partum period. This is one of the reasons why the authors recommend iron administration to all women after spontaneous delivery. In the authors' opinion examination of the blood count on the fourth day and assessment of the serum ferritin concentration one month after a spontaneous delivery in selected mothers (e.g. after an above average peripartal blood loss) is desirable. Addition of folic acid to iron is of no special value during the post-partum period. Iron substitution in women after spontaneous delivery should be, with regard to the long persisting sideropenia, administered at least for three months. The dose of 80 mg elemental iron per day is sufficient for mild or medium post-partum anaemia. Addition of mucoprotease and ascorbic acid to iron preparations is useful because it increases the compliance of the patients and thus also its effectiveness. The preparation Tardyferon meets the above criteria and is therefore a good choice for the treatment of post-partum anaemia.

• MeSH
• anemie z nedostatku železa diagnóza   farmakoterapie   prevence a kontrola   MeSH
• aplikace orální MeSH
• fixní kombinace léků MeSH
• léky s prodlouženým účinkem MeSH
• lidé MeSH
• muciny aplikace a dávkování   MeSH
• poruchy v puerperiu diagnóza   farmakoterapie   prevence a kontrola   MeSH
• těhotenství MeSH
• železnaté sloučeniny aplikace a dávkování   MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• klinické zkoušky MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• ferrous sulfate, mucin drug combination MeSH Prohlížeč
• fixní kombinace léků MeSH
• léky s prodlouženým účinkem MeSH
• muciny MeSH
• železnaté sloučeniny MeSH

OBJECTIVE OF STUDY: Assess interrelations between parameters of haemostasis, fibrinolysis, acute stage proteins and cytoadhesive molecules in gestational diabetes (GDM), which in susceptible women is actively induced by insulin resistance. METHODS: In 33 pregnant women where based on the glucose tolerance test (75 g glucose) GDM was revealed, repeatedly fibrinogen values were assessed (FBG 4.38 +/- 0.98 g/l), the antithrombin III activity (ATIII% 103.83 +/- 14.9), t-PA Ag(4.82 +/- 3.35 ng/ml), PAI-1 Ag (158.04 +/- 57.7 ng/ml), D-dimer (234.99 +/- 455.36 ng/ml), plasma proteins-orosomucoid (ORM 0.506 +/- 0.14 g/l), C reactive protein (1.34 +/- 0.96 g/l), transferrin (3.77 +/- 0.79 g/l), prealbumin (1.86 +/- 0.83 g/l) and alpha-2-macroglobulin (A2M 2.01 +/- 0.62 g/l) and cytadhesive molecules sICAM-1 (230.8 +/- 57.76 ng/ml) and sE-selectin (35.50 +/- 16.55 ng/ml). These findings were compared with parameters of the glucose and lipid metabolism and some anthropometric data (BMI, weight increments during pregnancy and birth weight of the infant). RESULTS: After statistical evaluation in GDM positive correlations of FBG and BMI were found (r = 0.871, p = 0.007) and also with the weight increment during pregnancy (r = 0.934, p = 0.0007). Hyperfibrinogenaemia is however probably compensated in stabilized cases of GDM by a higher production of t-PA (FBG:t-PA Ag, r = 0.782, p = 0.003). In GDM a marginal positive correlation between the value of the "atheroindex" and the infant's length was found r = 0.744 p = 0.0547). sE-selectin levels in GDM correlated inversely with ATIII activity (r = -0.905, p = 0.0028). CONCLUSION: The higher body weight of pregnant women with GDM is probably associated with a higher risk of thrombophilia (elevated fibrinogen). If in pregnant women infection develops with release of inflammatory cytokines, inducing on the endothelium expression of E-selectin, deterioration of thrombophilia (due to a decline of ATIII) activity must be foreseen.

• MeSH
• E-selektin krev   MeSH
• fibrinolýza MeSH
• gestační diabetes krev   MeSH
• glukózový toleranční test MeSH
• hemostáza * MeSH
• lidé MeSH
• mezibuněčná adhezivní molekula-1 krev   MeSH
• proteiny akutní fáze analýza   MeSH
• těhotenství MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• E-selektin MeSH
• mezibuněčná adhezivní molekula-1 MeSH
• proteiny akutní fáze MeSH

Non-insulin dependent diabetes mellitus (NIDDM) is connected with a higher incidence of macrovascular atherosclerotic disorders. The aim of the study was to detect any difference in levels of "cardiovascular risk factors"--fibrinogen, PAI-1 and inflammation response (documented by an increase of protein of acute phase orosomucoid) and of soluble cytoadhesive molecule sE-selectin and sICAM-1 (as markers of endothelial dysfunction) in blood plasma of 118 patients with NIDDM in comparison to the levels in blood plasma of 59 healthy persons as a control group. We observed higher levels of fibrinogen (fibrinogen level was 3.44 +/- 1.02 g/l in NIDDM pts versus 2.44 +/- 0.55 g/l in control group, p < 0.01) and PAI-1 Ag concentration was 159.7 +/- 110.3 ng/ml in NIDDM pts versus 51.43 +/- 24.64 ng/ml in control group, p < 0.01) together with an increase of acute phase protein orosomucoid as a "inflammatory response marker" (orosomucoid concentration was 0.85 +/- 0.23 g/l in NIDDM pts versus 0.54 +/- 0.18 g/l in control group, p < 0.01) in patients with NIDDM. The increase of these "cardiovascular risk factors" levels will be probably induced by higher activity of inflammatory cytokines IL-1 beta and/or TNF alpha in NIDDM patients, because both are inducers of orosomucoid fibrinogen and PAI-1 synthesis. This hypothesis is also supported by observation of higher levels of soluble cytoadhesive molecules sE-selectin (sE-selectin level was 64.25 +/- 26.8 ng/ml in NIDDM pts versus 46.64 +/- 29.57 ng/ml in control group, p < 0.01) and sICAM-1 (sICAM-1 level was 307.71 +/- 86.2 ng/ml in NIDDM pts versus 255.6 +/- 58.0 ng/ml in control group, p < 0.01) in patients with NIDDM. Both cytoadhesive molecules are produced by endothelial cells which are influenced by IL-1 beta and/or TNF alpha. According to these findings we suppose that an "inflammation" plays an important role in the evolution of atherosclerotic process at NIDDM together with the known influence of glucose and lipid metabolism pathology.

• MeSH
• diabetes mellitus 2. typu krev   komplikace   MeSH
• E-selektin krev   MeSH
• hemostáza * MeSH
• inhibitor aktivátoru plazminogenu 1 krev   MeSH
• kardiovaskulární nemoci etiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mediátory zánětu krev   MeSH
• mezibuněčná adhezivní molekula-1 krev   MeSH
• orosomukoid analýza   MeSH
• rizikové faktory MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• E-selektin MeSH
• inhibitor aktivátoru plazminogenu 1 MeSH
• mediátory zánětu MeSH
• mezibuněčná adhezivní molekula-1 MeSH
• orosomukoid MeSH

BACKGROUND: Cytokines were shown both to enhance tumour growth and formation of metastases and to inhibit proliferation of tumour cells. TNF alpha may mediate apoptosis and necrosis of cancer cells, the exact role of IL-2 remains to be elucidated. Plasma levels of TNF alpha and TNF and IL-2 soluble receptors (sTNF-R, sIL-2R) should thus be in some relation to the biological characteristics of the breast cancer. METHODS AND RESULTS: Plasma levels of TNF alpha, sTNF-R I and II and sIL-2R were measured in 31 women with different stages of breast cancer both before the institution of the therapy and after 3 months of the treatment. Plasma levels of both types of sTNF-Rs were higher in patients with breast cancer than in controls (sTNF-R I-2166.6 +/- 568.9 VS. 1121.3 +/- 260.6 pg/ml, p < 0.001, sTNF-R II-3792.8 +/- 958.9 vs. 1996.2 +/- 404.3 pg/ml, p < 0.001) with no significant difference between clinical stages. Plasma levels of both sTNF-R (0.871, p < 0.001) and sIL-2R tightly correlated one with each other. Plasma levels of TNF alpha decreased after treatment (from 3.92 +/- 1.86 to 3.40 +/- 1.15 pg/ml, p < 0.001), but plasma levels of sTNF-Rs and sIL-2R were not influenced by the treatment. CONCLUSIONS: Plasma levels of soluble TNF receptors may thus serve as a non-specific marker of the untreated breast cancer. Their relation to other biologic characteristics of this tumour is not clear. It remains also to be clarified if the long-term treatment leads to the normalization of sTNF-Rs plasma levels.

• MeSH
• dospělí MeSH
• karcinom krev   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory prsu krev   terapie   MeSH
• receptory interleukinu-2 krev   MeSH
• receptory TNF krev   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• TNF-alfa analýza   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• receptory interleukinu-2 MeSH
• receptory TNF MeSH
• TNF-alfa MeSH